Patrick Gueule

This inventor holds 32 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Sanofi-Synthelabo, Elf Sanofi. Active years: 1992-2013.

USPTO Granted Patents = 32

% Patents Active = 81.3

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 200(Granted Patents)

Location History:

Teyrand, FR (1994 - 1998)
Teyran, FR (1992 - 2009)
Paris, FR (2013)

Company Filing History:

Societe Anonyme Sanofi

patents

6. 1 out of 834,411

Other

patents

Years Active: 1992-2013

Loading Chart...

Areas of Expertise:

Thiophene Derivatives

Piperidine Compounds

Heterocyclic Chemistry

NK3 Receptor Antagonists

Polycyclic Amines

Pharmaceutical Compositions

Medicinal Products

Diagnostic Tools

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8410137 - Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof (2013-04-02),

2. 7632852 - [object Object] (2009-12-15),

3. 7541361 - N-[4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use (2009-06-02),

4. 6951940 - Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them (2005-10-04),

5. 6710042 - Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them (2004-03-23),

6. 6642233 - 1-Phenacyl-3-phenyl-3-(piperidylethyl)piperidine derivatives, process for the preparation thereof and pharmaceutical compositions containing them (2003-11-04),

7. 6506750 - Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives (2003-01-14),

8. 6294537 - Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools (2001-09-25),

9. 6291672 - Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them (2001-09-18),

10. 6242637 - Substituted heterocylic compounds, method of preparing them and pharmaceutical compositions in which they are present (2001-06-05),

11. 6124316 - Compounds which are specific antagonists of the human NK3 receptor and (2000-09-26),

12. 6028082 - Human NK.sub.3 receptor-selective antagonist compounds, method for (2000-02-22),

13. 6011154 - Substituted heterocyclic compounds, method of preparing them and (2000-01-04),

14. 5977359 - Substituted heterocyclic compounds, method of preparing them and (1999-11-02),

15. 5965580 - Piperidine derivatives, process for obtaining them and pharmaceutical (1999-10-12),

Title: Innovations by Patrick Gueule: A Profile of a Prominent Inventor

Introduction

Patrick Gueule, based in Teyran, France, is a distinguished inventor with an impressive portfolio of 32 patents. His work has significantly contributed to the field of pharmaceuticals, particularly in the development of novel therapeutic compounds. This article delves into his latest patents, career highlights, and collaborations within the industry.

Latest Patents

Among Patrick Gueule's recent innovations is the patent for thiophene-2-carboxamide derivatives, which encompasses compounds defined by a specific molecular formula. The invention details that the compounds consist of a saturated heterocyclic radical and outlines various substituents that allow for diverse therapeutic applications. Additionally, the patent discusses methods for preparing these compounds and their potential uses in treatment, showcasing Gueule's contributions to medicinal chemistry.

Career Highlights

Throughout his prolific career, Patrick Gueule has been associated with prominent companies, including Sanofi and Sanofi-Synthelabo. His work at these reputable organizations has facilitated the advancement of various therapeutic solutions, making a tangible impact on healthcare.

Collaborations

Patrick Gueule has collaborated with notable colleagues, including Xavier Emonds-Alt and Vincenzo Proietto. Their joint efforts showcase the collaborative spirit prevalent in research and innovation, emphasizing the importance of teamwork in the successful development of new therapeutic agents.

Conclusion

With 32 patents to his name, Patrick Gueule exemplifies the innovative spirit of modern inventors in the pharmaceutical field. His latest patents reflect his commitment to advancing medical science and improving therapeutic strategies. Through his collaborations and career achievements, Gueule continues to inspire future generations of inventors and researchers.